ArticlePsycho-oncology2026
Advancing Dimensional Models of Psychopathology in Cancer: Insights From Applying the Hierarchical Taxonomy of Psychopathology (HiTOP).
Article in Psycho-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectiveCancer survivors, defined as those living with or beyond a cancer diagnosis, experience more than double the prevalence of psychopathology when compared to the general population. Categorical diagnostic systems, such as the Diagnostic and Statistical Manual of Mental Disorders (DSM), remain dominant in psycho-oncology despite concerns about reliability, validity, and clinical utility for this population. Dimensional frameworks, such as the Hierarchical Taxonomy of Psychopathology (HiTOP), offer a more precise alternative; however, they have not yet been widely applied in cancer survivors. Accordingly, the objective of this research was to examine the applicability of HiTOP to cancer survivors.
methodsData from 1389 participants in 28 countries (n = 728 cancer survivors; n = 661 community/psychiatric) were collected using the 405-item HiTOP-SR, alongside demographic, clinical, and cancer-specific measures. The HiTOP-SR normative sample (n = 780) was also used. Analyses included parametric, non-parametric, and factor analytic approaches.
resultsAll HiTOP-SR scales demonstrated strong homogeneity and reliability in cancer survivors. Cancer survivors showed significant elevations across Internalising and Somatoform spectra, with current cancer associated with additional elevations in domains of Thought Disorder and components of Disinhibited and Antagonistic psychopathology. An 11-factor model was developed and supported for both cancer and community/psychiatric samples, though the magnitudes of the factor loadings sometimes varied between samples. External validity was strong with theoretically aligned associations.
conclusionThe HiTOP-SR appears reliable within cancer survivors and provides utility in quantifying a broad array of psychopathology experienced. The results highlight the potential applicability and utility of HiTOP to improve cancer research and clinical practice in psycho-oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.